Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biosensor Chips Identify Antibiotic Treatment Faster

By LabMedica International staff writers
Posted on 14 Apr 2017
Bacterial infections are still a major cause of death in the Western world, and because of over and mistreatment antibiotics resistant bacterial stains are increasing every day. In the UK, it is estimated that 300,000 patients a year acquire infections in hospital, with over 9,000 dying from bacterial infections.

Silicon biosensor chips have been piloted which can rapidly identify the best antibiotics for treating bacterial infections. The system can direct clinicians to the best antibiotic treatment in around two to six hours, rather than upwards of two days, which is typical of conventional tests.

Scientists at the Technion Israeli Institute of Technology have developed special silicon biosensor chips to address the problem. Each chip contains thousands of nano wells, which are coated with a material, which allows bacteria to stick to the chip. Once the bacteria have stuck to the well, technicians use reflected visual light to count the bacteria, and to see whether the colony is growing. They can then add a different antibiotic in various dilutions to each chip to see which best inhibits bacterial growth, giving results within two to six hours.

Urinary Tract Infections (UTIs) for example, are a major health burden. Around half of all women in the West will have a UTI at some point. The major obstacle in the diagnosis and clinical management of UTI is the delay in our ability to isolate the bacteria causing the infection, and identify its susceptibility to certain antibiotics. This silicon well system can significantly cut the time needed to identify the correct antibiotic, from a couple of days down to just a few hours. Using the best antibiotics will also help prevent the rise of antibiotic resistant bacteria which are one of the main problems in hospital acquired infections.

Sarel Halachmi, MD, a clinical associate professor who led the study, said, “We are currently at initial testing stages using commercial bacteria solution and also human bacteria isolated from urine samples. The system is accurate, simple economical, and significantly shortens the time to accurate treatment recommendation and will save lives in the future.” The study was presented at the European Association of Urology congress held March 24-27, 2017, in London, UK.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.